Actively Recruiting
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Led by Chinese University of Hong Kong · Updated on 2026-03-18
594
Participants Needed
8
Research Sites
267 weeks
Total Duration
On this page
Sponsors
C
Chinese University of Hong Kong
Lead Sponsor
N
Nanfang Hospital, Southern Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Vonoprazan (VPZ), an oral potassium-competitive acid blocker (P-CAB) has emerged as an alternative potent acid-suppressant.It has a faster onset of action in 1 day (3-5 days in PPI), and is more stable in acidic condition than PPI. While many studies compared Vonoprazan against PPI in the treatment of reflux oesophagitis, H. Pylori eradication, and gastric ulcers; thus far, there is a paucity of data on use of Vonoprazan on bleeding peptic ulcers. We perform a multicenter randomized controlled trial (RCT) to compare the efficacy of oral Vonoprazan against standard high dose PPI therapy in bleeding peptic ulcers that had received successful endoscopic haemostasis We hypothesize that in patients with bleeding peptic ulcers, the use of acid pump inhibitors Vonoprazan would not be inferior to standard treatment of a bolus plus high dose PPI intravenous infusion at preventing recurrent bleeding after endoscopic haemostasis.
CONDITIONS
Official Title
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 618 years who had an endoscopy for anemia or upper GI bleeding symptoms and were found to have a non-variceal upper GI bleeding cause such as peptic ulcers, Dieulafoy's lesions, or Mallory Weiss tear with active bleeding or major signs of recent bleeding
- Presence of major bleeding signs including peptic ulcers with spurting or oozing bleeding (Forrest Ia and Ib), nonbleeding visible vessel (Forrest IIa), or adherent clot (Forrest IIb), with clot removal and confirmation of bleeding source
- Patients who received endoscopic hemostatic treatment with hemoclipping, thermocoagulation, or haemostatic forceps, and no evidence of bleeding after 3 minutes observation
You will not qualify if you...
- Lack of consent to participate
- Age under 18 years
- Pregnancy or breastfeeding
- Allergy or hypersensitivity to proton pump inhibitors, Vonoprazan, or any formulation components
- Bleeding caused by tumors or oesophageal varices
- Bleeding related to recent endoscopic treatments such as polypectomy, mucosal resection, or submucosal dissection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China
Actively Recruiting
2
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Not Yet Recruiting
3
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
Not Yet Recruiting
4
Shenzhen Pingshan District People's Hospital
Shenzhen, Guangdong, China
Not Yet Recruiting
5
The Second Affiliated Hospital The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen
Shenzhen, Guangdong, China
Not Yet Recruiting
6
Yangjiang People's Hospital of Guangdong Medical University
Yangjiang, Guangdong, China
Not Yet Recruiting
7
Zhuhai People's Hospital (Zhuhai Hospital Affiliated to Jinan University)
Zhuhai, Guangdong, China
Not Yet Recruiting
8
Prince of Wales Hospital
Hong Kong, Hong Kong SAR, China
Not Yet Recruiting
Research Team
X
xiaobei luo, PhD
CONTACT
B
bingyee suen, Bachelor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here